REGULATORY

Re-Pricing to Hit 23 Drugs in April; Takecab, GLP-1s, Vyndaqel/Vynmac, and More

January 19, 2022

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

A total of 23 drugs (APIs)/41 products will see their prices pared by special re-pricing rules in the FY2022 price revision in April, including Takeda Pharmaceutical’s acid reducer Takecab (vonoprazan) and all GLP-1 agents in injectable forms. A roster of…

To read the full story

Takecab Faces 15.8% Slash, GLP-1s 11.1% in FY2022 Drug Price Revision
March 4, 2022
Takecab Faces 2nd “Huge-Seller” Price Slash, All GLP-1 Injectables to Get Cut Too on Market Expansion
January 18, 2022

REGULATORY

Japan Approves AbbVie’s Aquipta, Novo’s IcoSema, Pfizer’s Tukysa, and More
February 20, 2026
Two iPSC-Derived Products Now in Line for Conditional Approval
February 20, 2026
PM Takaichi Keeps Cabinet Intact after Lower House Vote
February 18, 2026
LDP Returnees Set Sights on Social Security, Drug Policy as Special Diet Opens
February 18, 2026
10 Firms Win Approval for Bilanoa Generics, 2 Contenders for Fycompa
February 17, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Hisamitsu’s MBO: Is Shareholder Accountability Trust-Building or a Shackle?

By Hayate Horiguchi

Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…